Can B (CANB) 10-Q 17 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 11, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	333-208293
Entity Registrant Name	Can B Corp.
Entity Central Index Key	0001509957
Entity Tax Identification Number	20-3624118
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	960 South Broadway
Entity Address, Address Line Two	Suite 120
Entity Address, City or Town	Hicksville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11801
City Area Code	516
Local Phone Number	595-9544
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		3,325,814

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 114,992	$ 449,001
Accounts receivable, less allowance for doubtful accounts of $547,241 and $547,241, respectively	4,438,286	3,646,677
Inventory	3,087,338	2,553,438
Note receivable		2,898
Prepaid expenses		1,625
Total current assets	7,640,616	6,653,639
Property and equipment, net	6,792,188	7,052,926
Other assets:
Deposits	165,787	165,787
Intangible assets, net	376,486	369,015
Operating lease right-of-use-asset, net	2,009,212	2,220,134
Other noncurrent assets	13,139	13,139
Total other assets	2,564,624	2,768,075
Total assets	16,997,428	16,474,640
Current liabilities:
Accounts payable	2,153,587	1,163,284
Accrued expenses	157,343	2,407,528
Due to related party	210,434	218,273
Notes and loans payable, net	6,063,315	4,865,749
Warrant liabilities	195,678
Operating lease liability - current	809,010	808,223
Total current liabilities	9,589,367	9,463,057
Long-term liabilities:
Operating lease liability - noncurrent	1,159,867	1,392,068
Total long-term liabilities	1,159,867	1,392,068
Total liabilities	10,749,234	10,855,125
Commitments and contingencies (Note 14)
Stockholders’ equity:
Common stock, no par value; 1,500,000,000 shares authorized, 3,264,566 and 2,834,755 issued and outstanding at March 31, 2022 and December 31, 2021, respectively	76,219,018	49,676,847
Common stock issuable, no par value; 21,547 and 0 shares at March 31, 2022 and December 31, 2021, respectively	119,586
Treasury stock	(572,678)	(572,678)
Additional paid-in capital	6,206,822	5,635,003
Accumulated deficit	(81,251,556)	(77,766,659)
Total stockholders’ equity	6,248,194	5,619,515
Total liabilities and stockholders’ equity	16,997,428	16,474,640
Series A Preferred Stock [Member]
Stockholders’ equity:
Preferred stock	5,320,000	28,440,000
Series B Preferred Stock [Member]
Stockholders’ equity:
Preferred stock
Series C Preferred Stock [Member]
Stockholders’ equity:
Preferred stock	207,000	207,000
Series D Preferred Stock [Member]
Stockholders’ equity:
Preferred stock	$ 2	$ 2

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Allowance for doubtful accounts	$ 547,241	$ 547,241
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, no par value	$ 0	$ 0
Common stock, shares authorized	1,500,000,000	1,500,000,000
Common stock, shares issued	3,264,566	2,834,755
Common stock, shares outstanding	3,264,566	2,834,755
Common stock, issuable no par value	$ 0	$ 0
Common stock, issuable shares	21,547	0
Series A Preferred Stock [Member]
Preferred stock, shares authorized	20	20
Preferred stock, no par value	$ 0	$ 0
Preferred stock, shares issued	5	20
Preferred stock, shares outstanding	5	20
Series B Preferred Stock [Member]
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, par value	$ 0.001	$ 0.001
Series C Preferred Stock [Member]
Preferred stock, shares authorized	2,000	2,000
Preferred stock, shares issued	23	23
Preferred stock, shares outstanding	23	23
Preferred stock, par value	$ 0.001	$ 0.001
Series D Preferred Stock [Member]
Preferred stock, shares authorized	4,000	4,000
Preferred stock, shares issued	1,950	1,950
Preferred stock, shares outstanding	1,950	1,950
Preferred stock, par value	$ 0.001	$ 0.001

Consolidated Statement of Opera

Consolidated Statement of Operations - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues
Total revenues	$ 1,860,320	$ 306,940
Cost of revenues	1,190,330	76,795
Gross profit	669,990	230,145
Operating expenses	3,861,997	2,022,679
Loss from operations	(3,192,007)	(1,792,534)
Other income (expense):
Other income		5,564
Change in fair value of warrant liabilities	29,337
Interest expense	(322,227)	(392,787)
Other expense	(292,890)	(387,223)
Loss before provision for income taxes	(3,484,897)	(2,179,757)
Provision for (benefit from) income taxes		125
Net loss	$ (3,484,897)	$ (2,179,882)
Loss per share - basic and diluted	$ (1.10)	$ (3.58)
Weighted average shares outstanding - basic and diluted	3,154,004	608,797
Product Sales [Member]
Revenues
Total revenues	$ 1,310,396	$ 243,695
Service Revenue [Member]
Revenues
Total revenues	$ 549,924	$ 63,245

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($)	Series A Preferred Stock [Member]Preferred Stock [Member]	Series B Preferred Stock [Member]Preferred Stock [Member]	Series C Preferred Stock [Member]Preferred Stock [Member]	Series D Preferred Stock [Member]Preferred Stock [Member]	Common Stock [Member]	Common stock issuable [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance at Dec. 31, 2020	$ 28,440,000		$ 5,607,000		$ 30,874,270	$ 0	$ (572,678)	$ 2,724,689	$ (65,597,264)	$ 1,476,017
Beginning balance at Dec. 31, 2020	20		623		369,639		36,248
Issuance of common stock for services rendered					$ 66,135	0				66,135
Issuance of common stock for services rendered, shares					8,717
Issuance of common stock for asset acquisition					$ 137,673	0				137,673
Issuance of common stock for asset acquisition, shares					23,670
Sale of common stock					$ 2,866,000	0				2,866,000
Sale of common stock, shares					382,133
Conversion of Series C preferred stock to common stock			$ (1,350,000)		$ 1,350,000	0
Conversion of Series C preferred stock to common stock, shares			(150)		250,000
Net loss						0			(2,179,882)	(2,179,882)
Issuance of common stock in lieu of note repayments					$ 537,748	0				537,748
Issuance of common stock in lieu of note repayments, shares					77,017
Issuance of Series D preferred stock				$ 2		0				2
Issuance of Series D preferred stock, shares				1,950
Ending balance at Mar. 31, 2021	$ 28,440,000		$ 4,257,000	$ 2	$ 35,831,826	0	$ (572,678)	2,724,689	(67,777,146)	2,903,693
Ending balance at Mar. 31, 2021	20		473	1,950	1,111,177		36,248
Beginning balance at Dec. 31, 2021	$ 28,440,000		$ 207,000	$ 2	$ 49,676,847		$ (572,678)	5,635,003	(77,766,659)	5,619,515
Beginning balance at Dec. 31, 2021	20		23	1,950	2,834,755		36,248
Issuance of common stock for services rendered					$ 928,929	119,586				1,102,515
Issuance of common stock for services rendered, shares					130,825
Issuance of common stock for asset acquisition					$ 1,767,498					1,767,498
Issuance of common stock for asset acquisition, shares					190,505
Sale of common stock					$ 500,000					500,000
Sale of common stock, shares					51,282
Issuance of common stock in lieu of interest payments					$ 73,078					73,078
Issuance of common stock in lieu of interest payments, shares					10,150
Conversion of Series C preferred stock to common stock	$ (23,120,000)				$ 23,120,000
Conversion of Series C preferred stock to common stock, shares	(15)				33,345
Issuance of common stock for property and equipment					$ 98,666					98,666
Issuance of common stock for property and equipment, shares					13,704
Stock-based compensation								571,819		571,819
Net loss									(3,484,897)	(3,484,897)
Ending balance at Mar. 31, 2022	$ 5,320,000		$ 207,000	$ 2	$ 76,219,018	$ 119,586	$ (572,678)	$ 6,206,822	$ (81,251,556)	$ 6,248,194
Ending balance at Mar. 31, 2022	5		23	1,950	3,264,566		36,248

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities:
Net loss	$ (3,484,897)	$ (2,179,882)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,012,379
Depreciation	359,404	31,551
Amortization of intangible assets	10,026	43,860
Amortization of original-issue-discounts	158,815	351,535
Bad debt expense	2,898	47,452
Change in fair value of warrant liabilities	(29,337)
Stock-based interest expense	73,078
Stock-based consulting expense	1,102,515	66,135
Changes in operating assets and liabilities:
Accounts receivable	(791,609)	(73,401)
Inventory	(553,064)	13,003
Prepaid expenses	1,625	275,420
Deposits		(2,000)
Other noncurrent assets		7,347
Operating lease right-of-use asset	(20,492)	(155)
Accounts payable	985,710	(24,464)
Accrued expenses	(500,185)	(42,730)
Net cash used in operating activities	(2,094,530)	(1,486,329)
Investing activities:
Purchase of intangible assets		(177,530)
Net cash used in investing activities		(177,530)
Financing activities:
Proceeds received from notes and loans payable	1,382,300	175,000
Proceeds from issuance of Series D Preferred Stock		2
Proceeds from sale of common stock	500,000	2,932,135
Repayments of notes and loans payable	(75,250)	(224,000)
Amounts repaid to related parties, net	(7,839)
Deferred financing costs	(38,690)
Net cash provided by financing activities	1,760,521	2,883,137
(Decrease) Increase in cash and cash equivalents	(334,009)	1,219,278
Cash and cash equivalents, beginning of period	449,001	457,798
Cash and cash equivalents, end of period	114,992	1,677,076
Supplemental Cash Flow Information:
Income taxes paid		125
Interest paid	47,206
Non-cash Investing and Financing Activities:
Issuance of common stock in lieu of repayments of notes payable		537,748
Issuance of common stock for property and equipment	98,666
Issuance of common stock in asset acquisitions	1,767,498	137,673
Conversion of Series A Preferred stock to common stock	23,120,000
Debt discount associated with warrant liabilities	$ 225,015

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Organization and Description of Business	Note 1 – Organization and Description of Business Can B̅ Corp. was originally incorporated as WrapMail, Inc. (“WRAP”) in Florida on October 11, 2005. On May 15, 2017, WRAP changed its name to Canbiola, Inc. On January 16, 2020 Canbiola, Inc. changed its name to Can B̅ Corp. (the “Company”, “we”, “us”, “our”, “CANB”, “Can B̅” or “Registrant”). The Company acquired 100% of the membership interests in Pure Health Products, LLC, a New York limited liability company (“PHP” or “Pure Health Products”) effective December 28, 2018. The Company runs it manufacturing operations through PHP and holds and sells several of its brands through PHP as well. The Company’s durable equipment products, such as sam® units with and without CBD infused pads, are marketed and sold through its wholly-owned subsidiaries, Duramed Inc. (incorporated on November 29, 2018) and Duramed MI LLC (fka DuramedNJ, LLC) (incorporated on May 29, 2019) (collectively, “Duramed”). Duramed began operating on or about February 1, 2019. Most of the Company’s consumer products include hemp derived cannabidiol (“CBD”); however, the Company has just recently begun extracting cannabinol (“CBN”) and cannabigerol (“CBG”) for wholesale to third-parties looking to incorporate such compounds into their products through its wholly owned subsidiaries, Botanical Biotech, LLC (incorporated March 10, 2021), TN Botanicals, LLC and CO Botanicals LLC (both incorporated in August 2021). These three subsidiaries have also begun synthesizing Delta-8 and Delta-10 from hemp. Delta-8 and Delta-10 can produce similar, though less potent, effects as delta-9 (commonly referred to as THC); however, the legality of hemp derived Delta-8 and Delta-10 are in a gray area and considered a potential loophole at this point due to the 2018 hemp bill. The Company’s other subsidiaries did not have operations during the year ended December 31, 2021. The Company is in the business of promoting health and wellness through its development, manufacture and sale of products containing cannabinoids derived from hemp biomass and the licensing of durable medical devises. Can B̅’s products include oils, creams, moisturizers, isolate, gel caps, spa products, and concentrates and lifestyle products. Can B̅ develops its own line of proprietary products as well seeks synergistic value through acquisitions in the hemp industry. Can B̅ aims to be the premier provider of the highest quality hemp derived products on the market through sourcing the best raw material and offering a variety of products we believe will improve people’s lives in a variety of areas.

Liquidity

Liquidity	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity	Note 2 – Liquidity The consolidated financial statements have been prepared on a “going concern” basis, which contemplates the realization of assets and liquidation of liabilities in a normal course of business. As of March 31, 2022, the Company had cash and cash equivalents of $ 114,992 1,948,751 3,484,897 2,179,882

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 3 – Basis of Presentation and Summary of Significant Accounting Policies Basis of Financial Statement Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information, and with the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, these interim consolidated financial statements do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the management of the Company, as defined below, these unaudited consolidated financial statements include all adjustments necessary to present fairly the information set forth therein. Results for interim periods are not necessarily indicative of results to be expected for a full year. The consolidated balance sheet information as of December 31, 2021 was derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (“2021 Form 10-K”). The interim consolidated financial statements contained herein should be read in conjunction with the 2021 Form 10-K. Can B̅ Corp. and Subsidiaries Notes to Consolidated Financial Statements March 31, 2022 Principles of Consolidation The unaudited consolidated financial statements contained herein include the accounts of Can B Corp. and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated. Covid-19 Commencing in December 2019, the novel strain of coronavirus (“COVID-19”) began spreading throughout the world, including the first outbreak in the US in February 2020. On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic and recommended containment and mitigation measures worldwide. COVID-19 has disrupted and continues to significantly disrupt local, regional, and global economies and businesses. The COVID-19 outbreak is disrupting supply chains and affecting production and sales across a range of industries. The extent of the impact of COVID-19 on the Company’s operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, impact on the Company’s customers, employees and vendors, all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Company’s financial condition and/or results of operations is uncertain. In response to COVID-19, the Company put into place certain restrictions, requirements and guidelines to protect the health of its employees and clients, including requiring that certain conditions be met before employees return to the Company’s offices. Also, to protect the health and safety of its employees, the Company’s daily execution has evolved into a largely virtual model. The Company plans to continue to monitor the current environment and may take further actions that may be required by federal, state or local authorities or that it determines to be in the interests of its employees, customers, and partners. Management Estimates The preparation of financial statements and related disclosures in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses in those financial statements. Certain significant accounting policies that contain subjective management estimates and assumptions include those related to revenue recognition, inventory, goodwill, intangible assets and other long-lived assets, income taxes and deferred taxes. Descriptions of these policies are discussed in the Company’s 2021 Form 10-K. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and adjusts when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ significantly from those estimates and assumptions. Significant changes, if any, in those estimates resulting from continuing changes in the economic environment will be reflected in the consolidated financial statements in future periods. Significant Accounting Policies The Company’s significant accounting policies are described in “Note 3: Summary of Significant Accounting Policies” of our 2021 Form 10-K. Can B̅ Corp. and Subsidiaries Notes to Consolidated Financial Statements March 31, 2022 Segment reporting As of March 31, 2022, the Company reports operating results and financial data in one operating and reportable segment. The Chief Executive Officer, who is the chief operating decision maker, manages the Company as a single profit center in order to promote collaboration, provide comprehensive service offerings across the entire customer base, and provide incentives to employees based on the success of the organization as a whole. Although certain information regarding selected products or services is discussed for purposes of promoting an understanding of the Company’s business, the chief operating decision maker manages the Company and allocates resources at the consolidated level. Reclassifications Certain amounts in the prior year consolidated financial statements have been reclassified to conform to the current year presentation. These reclassification adjustments had no effect on the Company’s previously reported net loss.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4 – Fair Value Measurements The carrying value and fair value of the Company’s financial instruments are as follows: Schedule of Carrying Value and Fair value March 31, 2022 Level 1 Level 2 Level 3 Total Liabilities Warrant liabilities $ — $ — $ 195,678 $ 195,678 As of December 31, 2021 Level 1 Level 2 Level 3 Total Liabilities Warrant liabilities $ — $ — $ — $ — The fair value of the warrants outstanding was estimated using the Black-Scholes model. The application of the Black-Scholes model requires the use of a number of inputs and significant assumptions including volatility. The following reflects the inputs and assumptions used: Schedule of Fair Value of the Warrants Outstanding As of March 31, 2022 December 31, 2021 Stock price $ 5.55 N/A Exercise price $ 6.40 N/A Remaining term (in years) 0.98 N/A Volatility 110 % N/A Risk-free rate 1.63 % N/A Expected dividend yield — % — The warrant liabilities will be remeasured at each reporting period with changes in fair value recorded in other income (expense), net on the consolidated statements of operations. The change in fair value of the warrant liabilities was as follows: Schedule of Change in Fair Value of the Warrant Liabilities Warrant Liabilities Estimated fair value at March 22, 2022 $ 225,015 Change in fair value (29,337 ) Estimated fair value at March 31, 2022 $ 195,678 Can B̅ Corp. and Subsidiaries Notes to Consolidated Financial Statements March 31, 2022

Asset Acquisitions

Asset Acquisitions	3 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Asset Acquisitions	Note 5 – Asset Acquisitions Botanical Biotech Asset Acquisition On March 11, 2021, Company entered into an Asset Acquisition Agreement, which was fully executed on March 17, 2021, with multiple sellers (each, a “Seller” and, collectively, the “Sellers”), pursuant to which the Sellers agreed to sell certain assets to Company, and to transfer such assets to Botanical Biotech, LLC, a newly-formed, wholly-owned subsidiary of the Company (“Transferee” or “BB”). The assets purchased (“BB Assets”) include certain materials and manufacturing equipment, marketing or promotional designs, brochures, advertisements, concepts, literature, books, media rights, rights against any other person or entity in respect of any of the foregoing and all other promotional properties, in each case primarily used, developed or acquired by the Sellers for use in connection with the ownership and operation of the BB Assets. In exchange for the BB Assets the Company will pay the Seller a maximum of $ 355,057 10 In conjunction with the BB asset acquisition, the Company entered into employment agreements with two sellers. The Company and BB entered into an employment agreement with Lebsock dated March 11, 2021 (the “Lebsock Agreement”) pursuant to which Lebsock will serve as the President of BB for a term of three (3) years. The term of the Lebsock Agreement will automatically renew for an additional 3-year term unless other terminated by either party. Lebsock will receive a base salary equal to $ 120,000 3 100,000 Effective March 16, 2021, BB entered into a Consulting Agreement (the “Schlosser Agreement”) with Schlosser pursuant to which Schlosser has agreed to provide consulting services to BB for a period of 3 months in exchange for compensation equal to $ 10,000 CO Botanicals Asset Acquisition On August 12, 2021, The Company and CO Botanicals LLC (“COB”), a newly-formed, wholly-owned subsidiary of the Company entered into an Equipment Acquisition Agreement (the “TWS Agreement”) with TWS Pharma, LLC, (“TWS Pharma”) and L7 TWS Pharma, LLC (“L7 TWS” and, collectively with TWS Pharma, “TWS”). Pursuant to the TWS Agreement, COB agreed to purchase certain equipment and other assets from TWS (the “TWS Assets”) for a total purchase price equal to $ 5,316,774 1,250,000 6 100,000 4,066,774 0.62 that $1,750,000 of the TWS Shares will be withheld in escrow for a period of ninety (90) days from the closing date, which will be deducted from the purchase price should the Company discover any defects or misrepresentations. The first $500,000 of payments of the TWS Note will be secured by 1,000,000 shares of the Company’s common stock to be held in escrow. During the period ending March 31, 2022, the $1,750,000 of shares held in escrow were released and issued Can B̅ Corp. and Subsidiaries Notes to Consolidated Financial Statements March 31, 2022 TN Botanicals Asset Acquisition On August 13, 2021 the Company and TN Botanicals LLC (“TNB”), a newly-formed, wholly-owned subsidiary of the Company, entered into an Asset Purchase Agreement (the “MCB Agreement”) with Music City Botanicals, LLC, pursuant to which TNB agreed to purchase certain equipment, other assets, and intellectual property from MCB (the “MCB Assets”) for a total purchase price equal to $ 1,394,324 498,259 896,065 0.62 Imbibe Health Solutions Asset Acquisition On February 22, 2021, Can B̅ Corp. (the “Company”) entered into a material definitive agreement (“Acquisition Agreement”) with Imbibe Health Solutions, LLC, a Delaware limited liability company (“Imbibe”), pursuant to which Imbibe agreed to sell certain of its assets to the Company. The assets to be purchased (“Assets”) include the intellectual property rights and other intangible assets relating to its branded products containing CBD. In exchange for the Assets, the Company has agreed to pay Imbibe $ 120,000

Inventories

Inventories	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventories	Note 6 – Inventories Inventories consist of: Schedule of Inventories March 31, December 31, 2022 2021 Raw materials $ 1,033,171 $ 818,042 Finished goods 2,054,167 1,735,396 Total $ 3,087,338 $ 2,553,438

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 7 – Property and Equipment Property and equipment consist of: Summary of Property, Plant and Equipment March 31, December 31, 2022 2021 Furniture and fixtures $ 21,724 $ 21,724 Office equipment 12,378 12,378 Manufacturing equipment 7,117,188 7,018,522 Medical equipment 776,396 776,396 Leasehold improvements 26,902 26,902 Total 7,954,588 7,855,922 Accumulated depreciation (1,162,400 ) (802,996 ) Net $ 6,792,188 $ 7,052,926 Depreciation expense related to property and equipment was $ 359,404 31,551

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 8 – Intangible Assets Intangible assets consist of: Schedule of Intangible Assets March 31, December 31, 2022 2021 Technology, IP and patents $ 435,500 $ 418,003 Total 435,500 418,003 Accumulated amortization (59,014 ) (48,988 ) Intangible assets, net $ 376,486 $ 369,015 Amortization expense was $ 10,026 43,860 Can B̅ Corp. and Subsidiaries Notes to Consolidated Financial Statements March 31, 2022 Amortization expense for the balance of 2022, and for each of the next five years and thereafter is estimated to be as follows: Schedule of Estimated Amortization Expenses Nine months ended December 31, 2022 $ 32,640 Fiscal year 2023 43,520 Fiscal year 2024 43,520 Fiscal year 2025 43,520 Fiscal year 2026 43,520 Thereafter 169,766 Intangible assets, net $ 376,486

Notes and Loans Payable

Notes and Loans Payable	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Notes and Loans Payable	Note 9 – Notes and Loans Payable Convertible Promissory Notes In December 2020, the Company entered into a convertible promissory note (“ASOP Note I”) with Arena Special Opportunities Partners I, LP (“ASOP”). The principal balance of the note is $ 2,675,239 January 31, 2022 12% 3,426,280 3,426,280 0.45 2,400,997 In December 2020, the Company entered into a convertible promissory note (“ASOF Note I”) with Arena Special Opportunities Fund, LP (“ASOF”). The principal balance of the note is $ 102,539 January 31, 2022 12% 131,325 131,325 0.45 87,773 In May 2021, the Company entered into a convertible promissory note (“ASOP Note II”) with Arena Special Opportunities Partners I, LP. The principal balance of the note is $ 1,193,135 January 31, 2022 12% 1,529,670 1,529,670 0.45 1,073,250 Can B̅ Corp. and Subsidiaries Notes to Consolidated Financial Statements March 31, 2022 In May 2021, the Company entered into a convertible promissory note (“ASOF Note II”) with Arena Special Opportunities Fund, LP. The principal balance of the note is $ 306,865 January 31, 2022 12% 393,417 393,417 0.45 276,750 The maturity dates for the above notes were extended to April 30, 2022 300,000 The holders agreed to allow the Company to extend the notes for two additional 30-day periods for $100,000 per extension In March 2022, the Company entered into a convertible promissory note (“BL Note”) with Blue Lake Partners, LLC (“BL”). The principal balance of the note is $ 250,000 March 22, 2023 12% 39,062 39,062 6.40 0 0 250,000 In March 2022, the Company entered into a convertible promissory note (“MH Note”) with Mast Hill Fund, LP (“MH”). The principal balance of the note is $ 350,000 12% 39,062 39,062 6.40 0 0 350,000 In February 2022, the Company entered into a convertible promissory note (“Tysadco Note”) with Tysadco Partners, LLC (“Tysadco”). The principal balance of the note is $ 450,000 July 25, 2022 12% 350,000 100,000 TWS Note On August 12, 2021, pursuant to an Equipment Acquisition Agreement, the Company entered into a twelve-month promissory note of $ 1,250,000 100,000 6% 1,050,000 Other Loans On November 18, 2021, the Company entered into a $ 100,000 10% 3,000,000 100,000 On February 2, 2022, the Company entered into a Future Receivable Sale and Purchase Agreement with a Purchaser. Pursuant to the terms of the agreement, the Company sold an aggregate of $ 136,000 100,000 2,833 116,167 On February 11, 2022, the Company entered into a $ 150,000 16% 2,000,000 150,000 On March 3, 2022, the Company entered into a Receivable Purchase and Sale Agreement with a Buyer. Pursuant to the terms of the agreement, the Company sold an aggregate of $ 350,00 250,000 182,083

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders’ Equity	Note 10 – Stockholders’ Equity Preferred Stock Each share of Series A Preferred Stock is convertible into 218 shares of CANB common stock and is entitled to 4,444 pari passu pari passu 15 33,345 Can B̅ Corp. and Subsidiaries Notes to Consolidated Financial Statements March 31, 2022 Each share of Series B Preferred Stock has the first preference to dividends, distributions and payments upon liquidation, dissolution and winding-up of the Company, and is entitled to an accrued cumulative but not compounding dividend at the rate of 5% per annum whether or not declared. After six months of the issuance date, such share and any accrued but unpaid dividends can be converted into common stock at the conversion price which is the lower of (i) $0.0101; or (ii) the lower of the dollar volume weighted average price of CANB common stock on the trading day prior to the conversion day or the dollar volume weighted average price of CANB common stock on the conversion day The shares of Series B Preferred Stock have no voting rights Each share of Series C Preferred Stock has preference to payment of dividends, if and when declared by the Company, compared to shares of our common stock. Each Preferred Series C share is convertible into 25,000 Each share of Series D Preferred Stock has 10,000 shares of voting rights only pari passu to common shares voting with no conversion rights and no equity participation On February 8, 2021, the Company’s Board of Directors approved the designation of the Series D Preferred Shares and the number of shares constituting such series, and the rights, powers, preferences, privileges and restrictions relating to such series. On March 27, 2021, the Company filed an amendment to its articles of incorporation to authorize 4,000 0.001 pari passu Each Series D Preferred Share shall have voting rights equal to 667 shares of Common Stock, adjustable at any recapitalization of the Company’s stock. In the event of a liquidation event, whether voluntary or involuntary, each holder shall have a liquidation preference on a per-share amount equal to the par value of such holder’s Series D Preferred Shares. The holders shall not be entitled to receive distributions made or dividends paid to the Company’s other stockholders. Except as otherwise required by law, for as long as any Series D Preferred Shares remain outstanding, the Company shall have the option to redeem any outstanding share of Series D Preferred Shares at any time for a purchase price of par value per share of Series D Preferred Shares (“Price per Share”) 600 150 collectively representing 1,300,000 voting shares Common Stock For the three months ended March 31, 2022, the Company issued an aggregate of 51,282 In addition, for the three months ended March 31, 2022, the Company issued an aggregate of 190,505 13,704 130,825 10,150 Can B̅ Corp. and Subsidiaries Notes to Consolidated Financial Statements March 31, 2022

Stock Options

Stock Options	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock Options	Note 11 – Stock Options A summary of stock options activity for the three months ended March 31, 2022 is as follows: Summary of Stock Options Activity Option Shares Weighted Average Weighted Average Remaining Outstanding, January 1, 2022 377,654 $ 6.11 4.46 Granted 79,013 5.10 4.77 Exercised - - - Forfeited - - - Expired - - - Outstanding, March 31, 2022 456,666 $ 5.93 4.31 Schedule of Non-Vested Option Shares Option Shares Weighted Average Non-vested options, January 1, 2022 - $ - Granted 79,013 7.24 Vested (79,013 ) 7.24 Forfeited - - Non-vested options, March 31, 2022 - $ -

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 12 – Income Taxes The Company’s income tax provisions for the three months ended March 31, 2022 and 2021 reflect the Company’s estimates of the effective rates expected to be applicable for the respective full years, adjusted for any discrete events, which are recorded in the period that they occur. These estimates are reevaluated each quarter based on the Company’s estimated tax expense for the full year. The estimated effective tax rate includes the impact of valuation allowances in various jurisdictions.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 13 – Related Party Transactions For the three months ended March 31, 2022 and 2021, the Company paid fees to a service provider that is a relative of a director for professional services in the amount of $ 0 9,900 0 5,000 At March 31, 2022, the Company has amounts due to a director of the Company of approximately $ 210,434 Can B̅ Corp. and Subsidiaries Notes to Consolidated Financial Statements March 31, 2022

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14 – Commitments and Contingencies Lease Agreements The Company leases office space in numerous medical facilities offices under month-to-month agreements. Rent expense for the three months ended March 31, 2022 and 2021 was $ 203,017 71,448 At March 31, 2022, the future minimum lease payments under non-cancellable operating leases were: Schedule of Future Minimum Lease Payments Under Non-cancellable Operating Leases Nine months ended December 31, 2022 $ 809,010 Fiscal year 2023 832,893 Fiscal year 2024 326,974 Total $ 1,968,877

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 15 – Subsequent Events On April 13, 2022, the Company entered into an Amendment to Transactional Documents with Arena Special Opportunities Partners I, LP, a Delaware limited partnership (the “ASOP”) and Arena Special Opportunities Fund, LP, a Delaware limited partnership (“ASOF” and, collectively with ASOP, the “Holders”) whereby the holders extended the maturity date of certain previously issued promissory notes to April 30, 2022 in exchange for $ 300,000 100,000 On April 24, 2022, the Company entered into securities purchase agreements and related agreements with an investor for the sale of $ 150,000 The Company evaluates subsequent events and transactions that occur after the balance sheet date up to the date that the condensed consolidated financial statements are issued and as of that date, except as reported below, there were no subsequent events that required adjustment or disclosure in the consolidated financial statements.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Financial Statement Presentation	Basis of Financial Statement Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information, and with the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, these interim consolidated financial statements do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the management of the Company, as defined below, these unaudited consolidated financial statements include all adjustments necessary to present fairly the information set forth therein. Results for interim periods are not necessarily indicative of results to be expected for a full year. The consolidated balance sheet information as of December 31, 2021 was derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (“2021 Form 10-K”). The interim consolidated financial statements contained herein should be read in conjunction with the 2021 Form 10-K. Can B̅ Corp. and Subsidiaries Notes to Consolidated Financial Statements March 31, 2022
Principles of Consolidation	Principles of Consolidation The unaudited consolidated financial statements contained herein include the accounts of Can B Corp. and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated.
Covid-19	Covid-19 Commencing in December 2019, the novel strain of coronavirus (“COVID-19”) began spreading throughout the world, including the first outbreak in the US in February 2020. On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic and recommended containment and mitigation measures worldwide. COVID-19 has disrupted and continues to significantly disrupt local, regional, and global economies and businesses. The COVID-19 outbreak is disrupting supply chains and affecting production and sales across a range of industries. The extent of the impact of COVID-19 on the Company’s operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, impact on the Company’s customers, employees and vendors, all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Company’s financial condition and/or results of operations is uncertain. In response to COVID-19, the Company put into place certain restrictions, requirements and guidelines to protect the health of its employees and clients, including requiring that certain conditions be met before employees return to the Company’s offices. Also, to protect the health and safety of its employees, the Company’s daily execution has evolved into a largely virtual model. The Company plans to continue to monitor the current environment and may take further actions that may be required by federal, state or local authorities or that it determines to be in the interests of its employees, customers, and partners.
Management Estimates	Management Estimates The preparation of financial statements and related disclosures in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses in those financial statements. Certain significant accounting policies that contain subjective management estimates and assumptions include those related to revenue recognition, inventory, goodwill, intangible assets and other long-lived assets, income taxes and deferred taxes. Descriptions of these policies are discussed in the Company’s 2021 Form 10-K. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and adjusts when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ significantly from those estimates and assumptions. Significant changes, if any, in those estimates resulting from continuing changes in the economic environment will be reflected in the consolidated financial statements in future periods.
Significant Accounting Policies	Significant Accounting Policies The Company’s significant accounting policies are described in “Note 3: Summary of Significant Accounting Policies” of our 2021 Form 10-K. Can B̅ Corp. and Subsidiaries Notes to Consolidated Financial Statements March 31, 2022
Segment reporting	Segment reporting As of March 31, 2022, the Company reports operating results and financial data in one operating and reportable segment. The Chief Executive Officer, who is the chief operating decision maker, manages the Company as a single profit center in order to promote collaboration, provide comprehensive service offerings across the entire customer base, and provide incentives to employees based on the success of the organization as a whole. Although certain information regarding selected products or services is discussed for purposes of promoting an understanding of the Company’s business, the chief operating decision maker manages the Company and allocates resources at the consolidated level.
Reclassifications	Reclassifications Certain amounts in the prior year consolidated financial statements have been reclassified to conform to the current year presentation. These reclassification adjustments had no effect on the Company’s previously reported net loss.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Carrying Value and Fair value	The carrying value and fair value of the Company’s financial instruments are as follows: Schedule of Carrying Value and Fair value March 31, 2022 Level 1 Level 2 Level 3 Total Liabilities Warrant liabilities $ — $ — $ 195,678 $ 195,678 As of December 31, 2021 Level 1 Level 2 Level 3 Total Liabilities Warrant liabilities $ — $ — $ — $ —
Schedule of Fair Value of the Warrants Outstanding	The fair value of the warrants outstanding was estimated using the Black-Scholes model. The application of the Black-Scholes model requires the use of a number of inputs and significant assumptions including volatility. The following reflects the inputs and assumptions used: Schedule of Fair Value of the Warrants Outstanding As of March 31, 2022 December 31, 2021 Stock price $ 5.55 N/A Exercise price $ 6.40 N/A Remaining term (in years) 0.98 N/A Volatility 110 % N/A Risk-free rate 1.63 % N/A Expected dividend yield — % —
Schedule of Change in Fair Value of the Warrant Liabilities	The warrant liabilities will be remeasured at each reporting period with changes in fair value recorded in other income (expense), net on the consolidated statements of operations. The change in fair value of the warrant liabilities was as follows: Schedule of Change in Fair Value of the Warrant Liabilities Warrant Liabilities Estimated fair value at March 22, 2022 $ 225,015 Change in fair value (29,337 ) Estimated fair value at March 31, 2022 $ 195,678

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of: Schedule of Inventories March 31, December 31, 2022 2021 Raw materials $ 1,033,171 $ 818,042 Finished goods 2,054,167 1,735,396 Total $ 3,087,338 $ 2,553,438

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Summary of Property, Plant and Equipment	Property and equipment consist of: Summary of Property, Plant and Equipment March 31, December 31, 2022 2021 Furniture and fixtures $ 21,724 $ 21,724 Office equipment 12,378 12,378 Manufacturing equipment 7,117,188 7,018,522 Medical equipment 776,396 776,396 Leasehold improvements 26,902 26,902 Total 7,954,588 7,855,922 Accumulated depreciation (1,162,400 ) (802,996 ) Net $ 6,792,188 $ 7,052,926

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consist of: Schedule of Intangible Assets March 31, December 31, 2022 2021 Technology, IP and patents $ 435,500 $ 418,003 Total 435,500 418,003 Accumulated amortization (59,014 ) (48,988 ) Intangible assets, net $ 376,486 $ 369,015
Schedule of Estimated Amortization Expenses	Amortization expense for the balance of 2022, and for each of the next five years and thereafter is estimated to be as follows: Schedule of Estimated Amortization Expenses Nine months ended December 31, 2022 $ 32,640 Fiscal year 2023 43,520 Fiscal year 2024 43,520 Fiscal year 2025 43,520 Fiscal year 2026 43,520 Thereafter 169,766 Intangible assets, net $ 376,486

Stock Options (Tables)

Stock Options (Tables)	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Stock Options Activity	A summary of stock options activity for the three months ended March 31, 2022 is as follows: Summary of Stock Options Activity Option Shares Weighted Average Weighted Average Remaining Outstanding, January 1, 2022 377,654 $ 6.11 4.46 Granted 79,013 5.10 4.77 Exercised - - - Forfeited - - - Expired - - - Outstanding, March 31, 2022 456,666 $ 5.93 4.31
Schedule of Non-Vested Option Shares	Schedule of Non-Vested Option Shares Option Shares Weighted Average Non-vested options, January 1, 2022 - $ - Granted 79,013 7.24 Vested (79,013 ) 7.24 Forfeited - - Non-vested options, March 31, 2022 - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments Under Non-cancellable Operating Leases	At March 31, 2022, the future minimum lease payments under non-cancellable operating leases were: Schedule of Future Minimum Lease Payments Under Non-cancellable Operating Leases Nine months ended December 31, 2022 $ 809,010 Fiscal year 2023 832,893 Fiscal year 2024 326,974 Total $ 1,968,877

Liquidity (Details Narrative)

Liquidity (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 114,992		$ 449,001
Working capital	1,948,751
Net loss	$ 3,484,897	$ 2,179,882

Schedule of Carrying Value and

Schedule of Carrying Value and Fair value (Details) - USD ($)	Mar. 31, 2022	Mar. 21, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 195,678	$ 225,015
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 195,678

Schedule of Fair Value of the W

Schedule of Fair Value of the Warrants Outstanding (Details)	3 Months Ended
	Mar. 31, 2022$ / shares
Fair Value Disclosures [Abstract]
Stock price	$ 5.55
Exercise price	$ 6.40
Remaining term (in years)	11 months 23 days
Volatility	110.00%
Risk free rate	1.63%
Expected dividend yield

Schedule of Change in Fair Valu

Schedule of Change in Fair Value of the Warrant Liabilities (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2022	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Estimated fair value Beginning	$ 225,015
Change in fair value	(29,337)	(29,337)
Estimated fair value Ending	$ 195,678	$ 195,678

Asset Acquisitions (Details Nar

Asset Acquisitions (Details Narrative)	Aug. 13, 2021USD ($)$ / shares	Aug. 12, 2021USD ($)$ / shares	Mar. 17, 2021USD ($)Integer	Mar. 16, 2021USD ($)	Mar. 11, 2021USD ($)	Feb. 22, 2021USD ($)
President [Member] | Company's Incentive Stock Option Plan [Member]
Stock bonus					$ 100,000
Lebsock Agreement [Member] | President [Member]
Base salary per year					$ 120,000
Schlosser Agreement [Member]
Consulting fees				$ 10,000
Equipment Acquisition Agreement [Member]
Purchase price		$ 5,316,774
Long-term Debt, Gross		$ 1,250,000
Debt interest rate		6.00%
Debt monthly payments due		$ 100,000
Shares Issued, Price Per Share | $ / shares		$ 0.62
Equipment Acquisition Agreement [Member] | Common Stock [Member]
Long-term Debt, Gross		$ 4,066,774
Debt Instrument, Description		that $1,750,000 of the TWS Shares will be withheld in escrow for a period of ninety (90) days from the closing date, which will be deducted from the purchase price should the Company discover any defects or misrepresentations. The first $500,000 of payments of the TWS Note will be secured by 1,000,000 shares of the Company’s common stock to be held in escrow. During the period ending March 31, 2022, the $1,750,000 of shares held in escrow were released and issued
Asset Purchase Agreement [Member]
Purchase price	$ 1,394,324
Long-term Debt, Gross	498,259
Asset Purchase Agreement [Member] | Common Stock [Member]
Long-term Debt, Gross	$ 896,065
Shares Issued, Price Per Share | $ / shares	$ 0.62
Acquisition Agreement [Member] | Imbibe Health Solutions Asset Acquisition [Member]
Payments to acquire assets						$ 120,000
Maximum [Member] | Asset Acquisition Agreement [Member] | Botanical Biotech, LLC, [Member]
Payments to acquire assets			$ 355,057
Number of trading days | Integer			10
Maximum [Member] | Lebsock Agreement [Member] | President [Member]
Percentage of annual increase					3.00%

Schedule of Inventories (Detail

Schedule of Inventories (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 1,033,171	$ 818,042
Finished goods	2,054,167	1,735,396
Total	$ 3,087,338	$ 2,553,438

Summary of Property, Plant and

Summary of Property, Plant and Equipment (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Furniture and fixtures	$ 21,724	$ 21,724
Office equipment	12,378	12,378
Manufacturing equipment	7,117,188	7,018,522
Medical equipment	776,396	776,396
Leasehold improvements	26,902	26,902
Total	7,954,588	7,855,922
Accumulated depreciation	(1,162,400)	(802,996)
Net	$ 6,792,188	$ 7,052,926

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 359,404	$ 31,551

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Technology, IP and patents	$ 435,500	$ 418,003
Total	435,500	418,003
Accumulated amortization	(59,014)	(48,988)
Intangible assets, net	$ 376,486	$ 369,015

Schedule of Estimated Amortizat

Schedule of Estimated Amortization Expenses (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Nine months ended December 31, 2022	$ 32,640
Fiscal year 2023	43,520
Fiscal year 2024	43,520
Fiscal year 2025	43,520
Fiscal year 2026	43,520
Thereafter	169,766
Intangible assets, net	$ 376,486	$ 369,015

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 10,026	$ 43,860

Notes and Loans Payable (Detail

Notes and Loans Payable (Details Narrative) - USD ($)	Apr. 30, 2022	Apr. 14, 2022	Mar. 03, 2022	Feb. 11, 2022	Feb. 02, 2022	Feb. 02, 2022	Nov. 18, 2021	Aug. 12, 2021	Mar. 31, 2022	Feb. 28, 2022	May 31, 2021	Dec. 31, 2020	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2021
Short-Term Debt [Line Items]
Repayments of related party debt													$ 7,839
Amortization of debt discount premium													158,815	$ 351,535
Notes Payable									$ 0				0			$ 5,000
Equipment Acquisition Agreement [Member]
Short-Term Debt [Line Items]
Total notes and loans payable								$ 1,250,000
Debt instrument, interest rate								6.00%
Debt instrument, face amount									1,050,000				1,050,000
Debt monthly payments due								$ 100,000
Unsecured Promissory Note Agreement [Member]
Short-Term Debt [Line Items]
Proceeds received from debt							$ 3,000,000
Unsecured Promissory Note Agreement [Member] | Lender [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate				16.00%
Debt instrument, face amount									150,000				150,000
Unsecured promissory note				$ 150,000
Proceeds received from debt				$ 2,000,000
Unsecured Promissory Note Agreement [Member] | Lender [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount									100,000				100,000
Unsecured promissory note							$ 100,000
Interest rate							10.00%
Future receivable sale and purchase agreement [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount			$ 182,083						116,167				$ 116,167
Aggregate future receivables					$ 136,000	$ 136,000
Proceeds from collection receivables			250,000			$ 100,000
Aggregate principal amount					2,833
Receivable Purchase and Sale Agreement [Member]
Short-Term Debt [Line Items]
Aggregate future receivables			$ 350
Common Stock [Member]
Short-Term Debt [Line Items]
Number of shares issued													51,282	382,133
Common Stock [Member] | Equipment Acquisition Agreement [Member]
Short-Term Debt [Line Items]
Total notes and loans payable								$ 4,066,774
ASOP Note I [Member] | Arena Special Opportunities Partners I, LP [Member]
Short-Term Debt [Line Items]
Total notes and loans payable												$ 2,675,239			$ 2,675,239
Debt maturity date												Jan. 31, 2022
Debt instrument, interest rate												12.00%			12.00%
Number of shares issued															3,426,280
Warrants exercise price												$ 0.45			$ 0.45
Debt instrument, face amount									2,400,997				$ 2,400,997
ASOP Note I [Member] | Arena Special Opportunities Partners I, LP [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Warrants to purchase common stock												3,426,280			3,426,280
ASOF Note I [Member] | Arena Special Opportunities Fund, LP [Member]
Short-Term Debt [Line Items]
Debt maturity date												Jan. 31, 2022
Debt instrument, interest rate												12.00%			12.00%
Number of shares issued															131,325
Warrants exercise price												$ 0.45			$ 0.45
Debt instrument, face amount									87,773			$ 102,539	87,773		$ 102,539
ASOF Note I [Member] | Arena Special Opportunities Fund, LP [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Warrants to purchase common stock												131,325			131,325
ASOP Note II [Member] | Arena Special Opportunities Partners I, LP [Member]
Short-Term Debt [Line Items]
Debt maturity date											Jan. 31, 2022
Debt instrument, interest rate											12.00%
Number of shares issued											1,529,670
Warrants exercise price											$ 0.45
Debt instrument, face amount											$ 1,193,135
Principal balance outstanding													1,073,250
ASOP Note II [Member] | Arena Special Opportunities Partners I, LP [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Warrants to purchase common stock											1,529,670
ASOF Note II [Member] | Subsequent Event [Member]
Short-Term Debt [Line Items]
Debt maturity date	Apr. 30, 2022
ASOF Note II [Member] | Subsequent Event [Member] | Holders [Member]
Short-Term Debt [Line Items]
Repayments of related party debt		$ 300,000
Debt instrument, payment terms		The holders agreed to allow the Company to extend the notes for two additional 30-day periods for $100,000 per extension
ASOF Note II [Member] | Arena Special Opportunities Partners I, LP [Member]
Short-Term Debt [Line Items]
Debt maturity date											Jan. 31, 2022
Warrants exercise price											$ 0.45
ASOF Note II [Member] | Arena Special Opportunities Fund, LP [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate											12.00%
Number of shares issued											393,417
Debt instrument, face amount									$ 276,750		$ 306,865		$ 276,750
ASOF Note II [Member] | Arena Special Opportunities Fund, LP [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Warrants to purchase common stock											393,417
BL Note [Member] | Blue lake partners LLC [Member]
Short-Term Debt [Line Items]
Debt maturity date									Mar. 22, 2023
Debt instrument, interest rate									12.00%				12.00%
Number of shares issued									39,062
Warrants exercise price									$ 6.40				$ 6.40
Debt instrument, face amount									$ 250,000				$ 250,000
Principal balance outstanding													250,000
Amortization of debt discount premium													$ 0	$ 0
BL Note [Member] | Blue lake partners LLC [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Warrants to purchase common stock									39,062				39,062
MH Note [Member] | Mast hill fund LP [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate									12.00%				12.00%
Number of shares issued									39,062
Warrants exercise price									$ 6.40				$ 6.40
Debt instrument, face amount									$ 350,000				$ 350,000
Amortization of debt discount premium													$ 0	$ 0
MH Note [Member] | Mast hill fund LP [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Warrants to purchase common stock									39,062				39,062
Tysadco Note [Member] | Tysadco partners LLC [Member]
Short-Term Debt [Line Items]
Debt maturity date										Jul. 25, 2022
Debt instrument, interest rate										12.00%
Debt instrument, face amount									$ 350,000	$ 450,000			$ 350,000
Tysadco Note [Member] | Tysadco partners LLC [Member] | Subsequent Event [Member]
Short-Term Debt [Line Items]
Notes Payable	$ 100,000

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	Mar. 27, 2021	Feb. 08, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Class of Stock [Line Items]
Preferred stock shares authorized			5,000,000		5,000,000
Common stock issued for property and equipment			$ 98,666
Common Stock [Member]
Class of Stock [Line Items]
Conversion of stock			33,345
Stock issued during the period			51,282	382,133
Common stock issued for asset acquisitions			190,505	23,670
Common stock issued for property and equipment			$ 98,666
Common shares issued for services rendered			130,825	8,717
Offering [Member]
Class of Stock [Line Items]
Stock issued during the period			51,282
Common Stock One [Member]
Class of Stock [Line Items]
Common stock issued for asset acquisitions			190,505
Common stock issued for property and equipment			$ 13,704
Common shares issued for services rendered			130,825
Common shares issued for interest repayments			10,150
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, voting rights			Each share of Series A Preferred Stock is convertible into 218 shares of CANB common stock and is entitled to 4,444 votes
Number of convertible shares			4,444
Conversion of stock			15
Preferred stock shares authorized			20		20
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, voting rights			The shares of Series B Preferred Stock have no voting rights
Dividend, description			Each share of Series B Preferred Stock has the first preference to dividends, distributions and payments upon liquidation, dissolution and winding-up of the Company, and is entitled to an accrued cumulative but not compounding dividend at the rate of 5% per annum whether or not declared. After six months of the issuance date, such share and any accrued but unpaid dividends can be converted into common stock at the conversion price which is the lower of (i) $0.0101; or (ii) the lower of the dollar volume weighted average price of CANB common stock on the trading day prior to the conversion day or the dollar volume weighted average price of CANB common stock on the conversion day
Preferred stock shares authorized			500,000		500,000
Preferred stock, par or stated value per share			$ 0.001		$ 0.001
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Number of convertible shares			25,000
Preferred stock shares authorized			2,000		2,000
Preferred stock, par or stated value per share			$ 0.001		$ 0.001
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, voting rights	collectively representing 1,300,000 voting shares	Each Series D Preferred Share shall have voting rights equal to 667 shares of Common Stock, adjustable at any recapitalization of the Company’s stock. In the event of a liquidation event, whether voluntary or involuntary, each holder shall have a liquidation preference on a per-share amount equal to the par value of such holder’s Series D Preferred Shares. The holders shall not be entitled to receive distributions made or dividends paid to the Company’s other stockholders. Except as otherwise required by law, for as long as any Series D Preferred Shares remain outstanding, the Company shall have the option to redeem any outstanding share of Series D Preferred Shares at any time for a purchase price of par value per share of Series D Preferred Shares (“Price per Share”)	Each share of Series D Preferred Stock has 10,000 shares of voting rights only pari passu to common shares voting with no conversion rights and no equity participation
Preferred stock shares authorized	4,000		4,000		4,000
Preferred stock, par or stated value per share	$ 0.001		$ 0.001		$ 0.001
Series D Preferred Stock [Member] | Stanley L. Teeple [Member]
Class of Stock [Line Items]
Stock issued during the period	600
Series D Preferred Stock [Member] | Marco alfonsi [Member]
Class of Stock [Line Items]
Stock issued during the period	600
Series D Preferred Stock [Member] | Pasquale ferro [Member]
Class of Stock [Line Items]
Stock issued during the period	600
Series D Preferred Stock [Member] | Philip Scala [Member]
Class of Stock [Line Items]
Stock issued during the period	150

Summary of Stock Options Activi

Summary of Stock Options Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Option shares, outstanding beginning	377,654
Weighted average exercise price, outstanding beginning	$ 6.11
Weighted average remaining contractual life years, outstanding ending	4 years 3 months 21 days	4 years 5 months 15 days
Option shares, granted	79,013
Weighted average exercise price, granted	$ 5.10
Weighted average remaining contractual life years, granted	4 years 9 months 7 days
Option shares, exercised
Weighted average exercise price, exercised
Option shares, forfeited
Weighted average exercise price, forfeited
Option shares, expired
Weighted average exercise price, expired
Option shares, outstanding ending	456,666	377,654
Weighted average exercise price, outstanding ending	$ 5.93	$ 6.11

Schedule of Non-Vested Option S

Schedule of Non-Vested Option Shares (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Share-Based Payment Arrangement [Abstract]
Non-vested options, beginning | shares
Weighted average grant-date fair value, non-vested options, beginning | $ / shares
Non-vested options, granted | shares	79,013
Weighted average grant-date fair value, granted | $ / shares	$ 7.24
Non-vested options, vested | shares	(79,013)
Weighted average grant-date fair value, vested | $ / shares	$ 7.24
Non-vested options, forfeited | shares
Weighted average grant-date fair value, forfeited | $ / shares
Non-vested options, ending | shares
Weighted average grant-date fair value, non-vested options, ending | $ / shares

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Notes payable, outstanding	$ 0		$ 5,000
Due to director	210,434		$ 218,273
Director [Member]
Related Party Transaction [Line Items]
Professional fees	$ 0	$ 9,900

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments Under Non-cancellable Operating Leases (Details)	Mar. 31, 2022USD ($)
Commitments and Contingencies Disclosure [Abstract]
Nine months ended December 31, 2022	$ 809,010
Fiscal year 2023	832,893
Fiscal year 2024	326,974
Total	$ 1,968,877

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 203,017	$ 71,448

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Apr. 24, 2022	Apr. 14, 2022	May 31, 2022	Mar. 31, 2022	Mar. 31, 2021
Subsequent Event [Line Items]
Repayments of related party debt				$ 7,839
Subsequent Event [Member]
Subsequent Event [Line Items]
Paid from future offering proceeds			$ 100,000
Subsequent Event [Member] | Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Proceeds from issuance of debt	$ 150,000
Subsequent Event [Member] | Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Debt instrument, payment terms		the holders extended the maturity date of certain previously issued promissory notes to April 30, 2022 in exchange for $300,000 and agreed to grant two additional extensions for 30 days each, each for an additional $100,000 per extension. Holders also waived certain defaults under the notes and granted consents required under the notes
Subsequent Event [Member] | Convertible Notes Payable [Member] | Holders [Member]
Subsequent Event [Line Items]
Repayments of related party debt		$ 300,000